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Pulmonary sarcoidosis is a debilitating inflammatory condition characterized by 
the presence of granulomatous lesions throughout the lung. Granulomas are a 
physiological response to inhaled antigens or particulate matter which cannot be 
properly degraded. To explore mechanisms of granuloma formation and maintenance 
our laboratory developed a murine model of pulmonary granulomatous inflammation 
elicited by multi-wall carbon nanotubes (MWCNT). We have found the MWCNT model 
bears striking similarities to pulmonary sarcoidosis pathophysiology, including increased 
expression of inflammatory mediators and decreased expression and activity of 
peroxisome proliferator activated receptor- (PPAR) in alveolar macrophages. PPAR 
is a known regulator of macrophage activation and serves a crucial role in pulmonary 
lipid homeostasis through the regulation of macrophage ATP-binding cassette (ABC) 
lipid transporter-G1 (ABCG1). Further studies demonstrated that alveolar macrophages 
obtained from sarcoidosis patients and MWCNT instilled animals have decreased gene 
expression and protein levels of ABCG1 and ABCA1, a complementary cholesterol 
transporter. These studies aim to further define the role of alveolar macrophage PPAR, 
ABCA1 and ABCG1 in pulmonary granulomatous inflammation. We hypothesized that 
deficiency of ABCA1 and ABCG1 would exacerbate MWCNT induced granuloma 
formation. To test this hypothesis, macrophage-specific ABCA1, ABCG1 or combined 
ABCA1/ABCG1 knockout mice were developed and evaluated following MWCNT 
instillation. We found that deficiency of ABCG1 but not ABCA1 leads to a significant 
upregulation of pro-inflammatory mediators and promotes pulmonary granuloma 
formation. Interestingly, the combined deficiency of ABCA1/ABCG1 leads to an 
exacerbated pulmonary inflammatory phenotype. We further hypothesized that 
upregulation of the PPAR-ABCG1 pathway would limit MWCNT induced granuloma 
formation and inflammation. To test this hypothesis, we administered the PPAR-
specific ligand rosiglitazone to MWCNT instilled animals and evaluated the effect on 
granulomatous inflammation. We found that the administration of rosiglitazone promotes 
the expression of alveolar macrophage ABCG1, limits the severity of MWCNT induced 
granuloma formation and reduced alveolar macrophage pro-inflammatory gene 
expression. These studies suggest that the PPAR-ABCG1 pathway, specifically the 
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Sarcoidosis is an enigmatic multisystem inflammatory disorder characterized by 
the presence of non-necrotizing granulomas. While any organ can be affected, lung 
involvement has been reported in more than 90% of clinical cases [23]. Diagnosis is 
dependent on excluding the presence of an infectious agent or a prior exposure to a 
material known to produce granulomatous lesions [137]. The clinical stages of 
pulmonary sarcoidosis are defined as hilar lymph node involvement (Stage I), 
granulomatous infiltrates into the parenchyma of the lung (Stage II), bilateral infiltrates 
without lymph node involvement (Stage III) and progressive pulmonary fibrosis (Stage 
IV) [137]. However, the clinical manifestation of the disease is variable, spontaneous 
remission has been reported in two thirds of individuals whereas progression is 
associated with significant morbidity and mortality [72;84]. The most common cause of 
sarcoidosis related death is respiratory failure, particularly among older individuals 
[24;72;129].  Recent studies also indicate that the incidence of sarcoidosis and related 
hospitalization has increased during the past few decades [43;46]. 
Despite extensive research, the etiology of this disease remain unclear. The 
prevalence of sarcoidosis varies around the world. High rates of sarcoidosis have been 
reported in Finland (28.2:100,000), while the incidence in Japan (3.7:100,000) is one of 
the lowest in the world [110]. In the United States, the incidence among African 
Americans (39:100,000) is 12 times higher than Caucasians (5:100,000) and this 
demographic has an increased rate of associated morbidity and mortality [67;94;120]. 
These observations suggested genetic predisposition may play a role in the 
pathophysiology of sarcoidosis. Bioinformatic studies have implicated changes in 
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specific human leukocyte antigen (HLA) genes which may influence susceptibility to the 
sarcoidosis, however, these changes varied between patient populations [20;32;119]. 
Similar inconsistencies have been found with non-HLA candidate genes identified 
through genome-wide search approaches [123]. These observations suggest that other 
environmental factors influence the pathogenesis of sarcoidosis. 
Due to the histological and clinical similarities between pulmonary sarcoidosis 
and mycobacterium infections, the involvement of infectious agents have been 
investigated. Utilizing polymerase chain reaction and mass spectrometry approaches, 
the presence of mycobacterial DNA and protein fragments have been identified in 
sarcoidosis lesions [52;105]. Further evidence which supports a role for a specific 
eliciting antigen is the Kveim reaction. First observed by Ansger Kveim in 1941, 
intradermal injection of sarcoidosis tissue homogenate produces histologically similar 
granulomas within several weeks [77]. Further studies conducted in the 1960’s found 
that 50-80% of sarcoidosis patients have a positive Kveim reaction [124].  Despite these 
observations, extensive studies have been performed to identify the presence of an 
active microorganism in clinical biopsy samples with no success [29;93]. These finding 
may suggest a role for microbial agents during the onset of sarcoidosis but, given the 
heterogeneity of the disease, there is likely more than one etiology. 
While the lungs and associated lymph nodes are the most commonly affected 
organ, cutaneous and ocular sarcoidosis are also reported in 25% of clinical cases [62]. 
A common feature of these organs is the continuous exposure to the external 
environment where particulate matter may play a role in propagation of the disease.  To 
identify potential environmental risk factors, the ACCESS (A Case Control Etiologic 
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Study of Sarcoidosis) study was conducted. Although a single causative antigen was 
not identified, a previous exposure to moldy environments, insecticides, industrial 
organic dust or metal particulates were associated with the development of sarcoidosis 
[75;101]. Other reports found the incidence of sarcoidosis to be most prevalent in rural 
areas [67]. Assessment of potential risk factors included the use of wood stoves and 
fireplaces [68]. These observations indicate that air-borne particulate matter may play a 
significant role in the disease.  
Further research will be required to determine how genetics, infectious agents 
and the environment contribute to the pathobiology of sarcoidosis. Currently, our 
understanding suggest the development of sarcoidosis results from an exuberant host 
immune response to a poorly soluble antigen in genetically susceptible individuals 
[25;97;101]. Macrophages are the primary immune cell tasked with the removal of 
foreign antigens. Understanding how these cells contribute to the formation of 
granulomas may lead to improved therapies for granulomatous diseases.  
Macrophages: 
 Macrophages are terminally differentiated monocytes named for the tissue in 
which they reside.  Since the original description by Metchnikoff, the macrophage has 
been recognized as the professional phagocyte of the immune system [99]. Alveolar 
macrophages are the predominant cell type found in the lower airways of healthy 
individuals and play an integral role in maintaining pulmonary homeostasis [41;125]. 
The unique environment of the lung plays a key role in shaping the phenotype of the 
alveolar macrophage [61]. The lower airways are coated in a lipid rich film, called 
surfactant, and are constantly exposed to the external environment. The alveolar 
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macrophage plays a role in both the regulation of surfactant catabolism and the 
clearance of inhaled particulate matter. The inability to efficiently clear surfactant or 
properly degrade inhaled antigens can result in significant pulmonary inflammation. 
 
Alveolar Macrophages and Lipid Homeostasis: 
Pulmonary surfactant is a complex mixture of approximately 90% lipids and 10% 
proteins [53]. Synthesized and secreted by alveolar type 2 cells, surfactant acts to lower 
the surface tension of the alveoli which prevents their collapse. Surfactant turnover is 
equally important to pulmonary homeostasis. Surfactant can be endocytosed and 
recycled by alveolar type 2 cells or catabolized by alveolar macrophages [140;141]. 
Catabolized lipids are removed from the macrophage by reverse cholesterol transport 
pathways specifically the transcription factor peroxisome proliferator activated receptor 
gamma (PPAR) and its downstream target ATP binding cassette lipid transporter-G1 
(ABCG1).  Deficiency of this pathway results in significant pulmonary lipid accumulation 
and pro-inflammatory inflammation [131]. 
 
Peroxisome Proliferator Activated Receptor - : 
PPAR is a ligand activated nuclear transcription factor which promotes lipid and 
glucose metabolism and negatively regulates macrophage activation by antagonizing 
the activity of pro-inflammatory mediators [49;132]. Evaluation of alveolar macrophages 
isolated from healthy individuals found constitutively high expression and nuclear 
localization of PPAR [27]. The deficiency of PPAR has been reported in several lung 
diseases including pulmonary hypertension, allergic airway inflammation, and 
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sarcoidosis [4;27;35;73]. The unique lipid rich environment of the lung coupled with the 
constant exposure to the environment suggest that alveolar macrophage PPAR may 
play a unique role in pulmonary homeostasis. 
To further investigate alveolar macrophage PPAR, macrophage-specific PPAR 
knockout mice (PPAR-KO) have been characterized. PPAR-KO animals demonstrate 
significant lipid accumulation in alveolar macrophages and the lower airways [7]. Further 
studies found PPAR-KO alveolar macrophages were deficient in the lipid transporter 
ABCG1 [7]. The expression of the complimentary lipid transporter ABCA1 is 
upregulated in these animals, likely compensating for the deficiency of ABCG1 
[7;45;134]. In addition to pulmonary lipid accumulation, PPAR-KO animals exhibit a 
pro-inflammatory pulmonary phenotype, characterized by elevated expression of 
interferon- and inducible nitric oxide synthase [88]. Restoration of PPAR via lenti-viral 
transduction significantly attenuated both pulmonary lipid accumulation and pulmonary 
inflammation [6;88]. These observations suggest that alveolar macrophage PPAR 
plays an integral role maintaining pulmonary homeostasis. 
 
ATP-Binding Cassette Lipid Transporters: 
The lipid transporters ABCA1 and ABCG1 play an important role in the export of 
catabolized lipids from the cell. Following phagocytosis, surfactant lipids are catabolized 
and effluxed to the extracellular acceptors apolipoprotein-A1 and high density 
lipoprotein, by ABCA1 and ABCG1 respectively [80;135]. In addition to reverse 
cholesterol transport, ABCA1 and ABCG1 play an important role in innate immune 
signaling pathways. Deficiency of either of these lipid transporters leads to macrophage 
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lipid accumulation and increased production of inflammatory mediators [70;106;146]. 
Evaluation of ABCA1 or ABCG1 knockout mice found macrophages from these animals 
have increased formation of lipid rafts, cholesterol rich membrane microdomains which 
organize cell signaling molecules such as toll like receptors [74;147]. Accumulating 
evidence has found that dyslipidemia, particularly dysregulation of macrophage reverse 
cholesterol transport pathways, can greatly influence innate immunity and promote 
pulmonary inflammation. Interestingly, lipid loaded macrophages have been observed in 
several lung diseases including pneumonia and pulmonary fibrosis [17]. 
 
Alveolar Macrophages and Inhaled Particulate Matter: 
In addition to surfactant catabolism, alveolar macrophages are also tasked with 
the clearance of particulate matter and other foreign antigens from the lower airways. 
The majority of inhaled particulate matter is arrested as it passes over the mucosal 
lining of the nasal cavity and bronchial tree, only a fraction reaches the lower airways 
where gas exchange is paramount. An overt inflammatory response to each inhaled 
inert particulate would significantly impede gas exchange. Interestingly, studies have 
found alveolar macrophages have a reduced capacity to elicit immune responses and 
limit the release of pro-inflammatory mediators following stimulus [55;81;85]. These 
observations suggest alveolar macrophages act to limit pulmonary inflammation. 
Alveolar macrophages likely play a role in the progression of sarcoidosis by retaining 
the eliciting antigen and propagating pulmonary granuloma formation. Intradermal 
injection of bronchoalveolar lavage (BAL) cell homogenate, which consisted 
predominately of macrophages, was found to elicit granulomatous inflammation similar 
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to the Kveim reagent [56]. Furthermore, as in other tissues of the body, the inability of 




The granuloma is a physiologic response to a foreign antigens which cannot be 
broken down by the mononuclear phagocyte system, intended to protect the 
surrounding tissue from further damage [107]. When an antigen is phagocytosed, the 
macrophage releases chemoattractants which recruit other immune cells to assist in the 
clearance of the substance. If the macrophages are unable to clear the material, a 
milieu of cytokines and chemokines are released which promote the fusion and 
transformation of macrophages into an epithelioid granuloma [3;102]. Sarcoidosis 
granulomas are non-necrotizing, indicating the absence of a necrotic core which is 
observed in other infectious granuloma where the eliciting agent can survive. The 
granuloma consist of epithelioid macrophages, fibroblast with occasional CD4+/CD8+ T-
cells associated with the periphery of the structure [1]. The presence of the granuloma 
in the lung can cause significant airway obstruction and as observed in progressive 
sarcoidosis, if unresolved can be replaced with collagen and other matrix proteins 







Granulomatous Lung Disease: 
 Granulomatous lung disease represents a significant health burden worldwide. 
However, investigating the mechanisms of pulmonary granuloma formation have been 
impeded by the lack of viable animal models.  Previous models have utilized various 
methods to induce granulomas, including the administration of pathogens or 
introduction of antigen bound sepharose beads injected into the tail vein of sensitized 
animals [33;63;76].  While these models advanced the understanding of granuloma 
formation they have suffered significant drawbacks including the presence of an active 
pathogens, eliciting granuloma formation from the pulmonary capillaries instead of the 
airways and relatively short resolution time, between 14 and 21 days. Characteristics 
which are not observed in pulmonary sarcoidosis. To investigate underlying 




Carbon nanomaterial are produced for use in industrial processes or as the 
byproducts of combustion. The interest in nanotechnology and its wide range of 
commercial applications began in 1985 with the generation of the “buckyball,” a 
spherical arrangement of carbon atoms which earned the 1996 Nobel Prize in 
Chemistry [78]. Further efforts led to the generation of elongated, cylindrical 
arrangements of carbon atoms referred to as carbon nanotubes (CNT) which can be 
generated as a single wall carbon nanotube (SWCNT) or, with the addition of 
consecutive layers of carbon, multiwall carbon nanotubes (MWCNT). These materials 
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have been shown to have incredibly unique characteristics.  Nanotubes are predicted to 
be stronger than steel and may conduct electricity better than copper [37].  Outside of 
manufacturing processes, MWCNT can also be found ubiquitously within our 
environment.  Particulate matter collected from the urban centers of El Paso and 
Houston Texas contained MWCNT, likely the byproducts of vehicle exhaust [98].  Indoor 
environments also harbor MWCNT of respirable sizes.  Samples collected from propane 
or natural gas flames, including those of typical stoves and heaters, contained 
particulates consisting of nearly pure carbon nanoparticles [12]. 
 
Nanomaterials and Respiratory Health: 
As the potential applications and production capacity of these materials 
increased, environmental exposure has become a concern.  The first study to evaluate 
the pulmonary toxicity of carbon nanotubes was conducted by Lam et al. in 2004. The 
authors found that intratracheal instillation of SWCNT induced dose dependent 
epithelioid granulomatous lesions in the lungs of mice at 7 and 90 days post instillation 
[79].  Studies utilizing MWCNT showed a similar pulmonary responses in Sprague-
Dawley rats 60 days post intratracheal instillation [96].  It was also determined that 
particle size influenced the toxicity of both types of CNT, ultrasonification or physical 
disruption increased the distribution and severity of granulomatous lesions [79;96].  
These observations suggested that particulate matter of respirable sizes, particularly 
carbon nanomaterials, can adversely impact human health [37;78].  Interestingly, 
granulomatous lesions have been reported in the lungs of firefighters and non-
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firefighting individuals present at the site of the September 2001 World Trade Center 
(WTC) disaster [34;65;92].  Further analysis of WTC dust and lung tissue from exposed 
individuals found the presence of carbon nanotubes. 
MWCNT Induced Model of Chronic Granuloma Formation: 
The observation that carbon nanotubes have the capacity to induce 
granulomatous lesions prompted Huizar et al. to investigate the use of purified MWCNT 
to generate a murine model of chronic granuloma formation. Following oropharyngeal 
instillation, pulmonary granulomas were first evident 10 days following instillation and 
persisted 90 days after exposure [58]. Characterization of the lesions found the 
presence of macrophages and CD3+ T-cells, characteristics of well-formed granulomas 
[58]. Further evaluation of granulomatous tissue collected by microdissection found 
increased expression of cellular adhesion molecules and matrix-remodeling proteins 
which had been reported in pulmonary sarcoidosis patients [58]. These observations 
suggest the MWCNT model could be used to investigate cellular and molecular 
mechanisms which contribute to the persistence of pulmonary granulomas.  
Our laboratory has previously demonstrated alveolar macrophages of healthy 
individuals exhibit constitutively high expression and activity of PPAR [27], a nuclear 
transcription factor and negative regulator of pro-inflammatory macrophage activation 
[116].  In contrast, alveolar macrophages isolated from sarcoidosis patients are deficient 
of PPAR gene expression and DNA binding activity [35].  Evaluation of alveolar 
macrophages following MWCNT instillation found reduced PPAR mRNA expression 
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and nuclear localization compared to sham instilled mice [59]. This observation suggest 
PPAR pathways may play a role in pulmonary granuloma formation. 
PPAR Deficiency Exacerbates MWCNT Induced Granulomatous Inflammation: 
To further evaluate the role of alveolar macrophage PPAR, macrophage-specific 
PPAR knockout mice (PPAR-KO) were utilized. Sixty days following MWCNT 
instillation, PPAR-KO animals were found to develop increased frequency and severity 
of pulmonary granulomas [59]. The expression of chemokine (C-C motif) ligand 2 
(CCL2) and osteopontin were also evaluated in wild-type and PPAR-KO animals 
following MWCNT instillation. Murine studies have found deficiency of CCL2 or 
osteopontin limits pulmonary granuloma formation [83;104]. The expression of CCL2 
and osteopontin are intrinsically elevated in PPAR-KO alveolar macrophages 
compared to wild-type animals [59].  Following MWCNT instillation, the expression of 
CCL2 and osteopontin was significantly increased in wild-type animals and further 
elevated in PPAR-KO bearing nanotubes [59]. [58;59].  These data suggest the 
expression of CCL2 and osteopontin correlate with the severity of pulmonary granuloma 
formation.  
 
PPAR Pathways are Dysregulated in MWCNT Model: 
 To further evaluate the effect of MWCNT induced PPAR deficiency, PPAR 
regulated genes were evaluated. Previous studies have demonstrated alveolar 
macrophage PPAR promotes the expression of the lipid transporter ABCG1, and limits 
alveolar macrophage lipid accumulation [6]. Evaluation of BAL cells from MWCNT 
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instilled animals found a significant decrease in both the expression and protein levels 
of ABCG1 and ABCA1 [16].  The deficiency of these lipid transporters also correlated 
with an increase of intracellular lipid accumulation in MWCNT instilled mice [16], a 
phenotype shown to promote pro-inflammatory macrophage activation [147]. These 
observations suggest that the deficiency of ABCA1 and ABCG1 may promote alveolar 
macrophage pro-inflammatory activation following the instillation of MWCNT. 
 
General Hypothesis: 
 Our previous studies have shown the MWCNT model bears striking similarity to 
pulmonary sarcoidosis, including the deficiency of alveolar macrophage PPAR and the 
PPAR-regulated cholesterol transporter ABCG1 [16;35;59]. Based on these 
observations, we hypothesized that deficiency of the PPAR-ABCG1 pathway and 
increased pulmonary lipid accumulation would promote MWCNT induced 
granulomatous inflammation. To address this hypothesis, macrophage specific ABCA1, 
ABCG1 or combined ABCA1/ABCG1 knockout mice were generated and evaluated for 
MWCNT induced granuloma formation and inflammation. To further confirm 
involvement of the PPAR-ABCG1 pathway, we administered the PPAR specific 
agonist rosiglitazone to MWCNT instilled animals. We hypothesized that administration 
of rosiglitazone would promote alveolar macrophage ABCG1 expression, limit carbon 





















 Pulmonary sarcoidosis is a chronic inflammatory condition characterized by 
granulomatous inflammation. We have developed a murine model of chronic 
granulomatous inflammation elicited by carbon nanotubes. Evaluation of alveolar 
macrophages from sarcoidosis patients or animals instilled with carbon nanotubes 
found decreased expression and protein content of the ATP-binding cassette lipid 
transporters ABCA1 and ABCG1. Previous studies have demonstrated that the 
deficiency of these genes in complete murine knockouts promotes pulmonary lipid 
accumulation and inflammation. To further evaluate the role of alveolar macrophage 
ABCA1 and ABCG1 we generated macrophage specific ABC-transporter deficient mice 
using the LysMCre system. We found that the deficiency of ABCG1 and to a further 
extent, combined deficiency of ABCA1/ABCG1 promote pulmonary lipid accumulation 
and pro-inflammatory alveolar macrophage gene expression. Interestingly, ABCA1 
deficiency did not affect pulmonary lipid homeostasis or inflammation. These 
observation suggest that alveolar macrophage ABCG1 acts as a critical regulator of 




Our laboratory has described a multi-wall carbon nanotube (MWCNT) induced 
murine model of chronic granuloma formation [58]. We have found that this model bears 
striking similarity to pulmonary sarcoidosis, a disease characterized by the presence of 
granulomatous inflammation. We have recently demonstrated that alveolar 
macrophages of both sarcoidosis patients and MWCNT instilled mice have reduced 
gene expression and protein content of the lipid transporters ATP-binding cassette lipid 
transporter-A1 (ABCA1) and ABCG1 [16]. ABCA1 and ABCG1 are transmembrane 
proteins which facilitate the transport of lipids across plasma membranes. [39;80]. The 
deficiency of these lipid transporters in the MWCNT model correlate with increased 
alveolar macrophage lipid accumulation, a phenotype shown to induce pro-inflammatory 
macrophage activation [139;147].  
ABCA1 and ABCG1 expression is variable throughout the body, however both 
are expressed in multiple cell types of the lung. The presence of ABCA1 has been 
found in type I and type II pneumocytes and alveolar macrophages [18;28;71]. ABCG1 
is expressed in type II pneumocytes, alveolar macrophages, T-lymphocytes, dendritic 
cells and airway smooth muscle cells [40;70].  Alveolar macrophage ABCA1 and 
ABCG1 are particularly important in the catabolism of pulmonary surfactant. Produced 
by type II pneumocytes, surfactant reduces the surface tension of the airways and 
prevents alveolar collapse [140;141]. Approximately 50% of surfactant is recycled by 
type II pneumocytes while the remaining is catabolized by alveolar macrophages 
[140;141]. Following catabolism, surfactant lipids are transferred to the extracellular 
acceptors apolipoprotein-A1 and high-density lipoprotein by ABCA1 and ABCG1 
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respectively [39;80]. Deficiency of either lipid transporter has been shown to promote 
pulmonary lipid accumulation. ABCA1 deficient mice develop progressive pulmonary 
lipid accumulation which is first observed at 4-months, although not as severe as 
animals evaluated at 7-, 12- or 18- months of age [19;90]. Surfactant producing, type II 
pneumocytes of these animals also demonstrate abnormal morphology and increased 
cholesterol content [19]. ABCG1 deficient animals develop lipid accumulation in the 
periphery of the lung as early as 3 weeks of age [143]. At 8 months, ABCG1 deficient 
animals have stark lipid accumulation in all parts of the lung and altered morphology of 
type 2 pneumocytes [11;70]. The observed changes in lung morphology were 
exacerbated by the administration of high-fat, high-cholesterol-diet [10]. While these 
observations are striking, and demonstrate an important role for ABCA1 and ABCG1 in 
pulmonary lipid homeostasis, establishing how specific cell types contribute to the 
phenotype is challenging in complete knockout animals. 
To determine the role of alveolar macrophage lipid transporter deficiency in 
granulomatous lung disease, our laboratory developed macrophage-specific knockout 
animals using the Cre/lox system. The Cre/lox system has become a powerful tool used 
to develop tissue specific knockout animals. Originally described by Nat Sternberg, the 
technique utilizes the bacteriophage DNA recombinase Cre, and the specific locus of 
crossover sequence loxP adapted for use in higher eukaryotes [144]. Briefly, a murine 
strain is developed which expresses the Cre recombinase protein in place of a gene 
found exclusively in a tissue of interest. In a separate mouse model, loxP sites – 
specific DNA sequences recognized by Cre recombinase – are inserted on either side 
of a specific gene intended to be deleted, or floxed. Following selective breeding 
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protocols, animals homozygous for Cre recombinase and the floxed gene are produced. 
During development, Cre recombinase is produced instead of the tissue specific gene, 
binds the loxP sites and excises the target gene of interest. Our studies utilized 
LysMCre knock-in mice, where the Cre recombinase gene has been substituted in place 
of lysozyme 2. Lysozyme 2 is only expressed in monocytes, mature macrophages and 
granulocytes. Here we describe the protocols used to develop macrophage-specific 





MATERIAL AND METHODS 
Mice: All studies were conducted in accordance with the National Institutes of 
Health guide for the use of laboratory animals and approved by the East Carolina 
University Institutional Animal Care and Use Committee.  C57Bl/6J wild-type mice were 
obtained from The Jackson Laboratory (Bar Harbor, ME).  Macrophage-specific ATP-
binding cassette (ABC) lipid transporter knockout mice were generated by crossing 
Abca1flox/floxAbcg1flox/flox double floxed mice (catalog#021067; Jackson Laboratory) with 
LyzMCre+/+ mice (catalog#004781;Jackson Laboratory) to generate LysMCre+/+-
Abca1flox/flox (ABCA1-KO), LysMCre+/+Abcg1flox/flox (ABCG1-KO) or 
LysMCre+/+Abca1flox/floxAbcg1flox/flox (ABCA1/ABCG1-DKO) animals. To confirm 
genotypes, tail biopsies were digested in lysis buffer (400mM NaCl, 100mM pH8.0 Tris, 
5mM EDTA, 0.2% SDS, 20g/mL RNaseA, 500g/mL proteinase K) overnight at 55⁰C 
with gentle shaking followed by phenol chloroform genomic DNA purification.  
Polymerase chain reaction (PCR) was further conducted using KAPA Biosystems 
master mix (catalog # KK5621) and specific primers for LysMCre, ABCA1 or ABCG1 
provided by The Jackson Laboratory (supplementary figure 1A).  Finally, each reaction 
mixture was separated with 2% agarose gel and photographed under ultraviolet 
illumination for identification of specific genotypes. 
Bronchoalveolar lavage (BAL):  Animals were euthanized by intraperitoneal 
injection of tribromoethanol.  BAL was performed as previously described [88]. Briefly, 
the trachea was canulated and lungs were sequentially lavaged with 1mL aliquots of 
0.2% lidocane solution in phosphate buffered saline totaling 5mL. Following 
centrifugation at 1800 RPM x 10 minutes at 4°C, supernatant was snap frozen on dry 
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ice as BAL fluid (BALF).  BAL cells were washed twice in 4mL chilled phosphate 
buffered saline and snap frozen as a pellet for further analysis.  Differential cell counts 
and mean alveolar macrophage diameter were determined from BAL cell cytospins, 
generated by centrifugation at 500 RPM x 5 minutes and subsequently stained with Diff 
Quick solution (Thermo Fisher Scientific. Waltham, MA). 
Analysis of Bronchoalveolar Lavage Fluid: Cholesterol content was evaluated 
using the Amplex Red Cholesterol Assay kit (Thermo Fisher Scientific. Waltham, MA) 
according to the manufacturer’s instructions in the presence of cholesterol esterase.  
RNA Purification and Analysis: Total RNA was isolated using the miRNeasy 
Micro Kit (Qiagen. Hilden, Germany) according to manufacturer’s protocol. Specific 
primers were obtained from Qiagen for ATP binding cassette (ABC) transporter-A1 
(Abca1, PPM03952F), Abcg1 (PPM03895A), chemokine (C-C motif) ligand-2 (Ccl2, 
PPM03151G), Glyceraldehyde-3-phosphate-dehydrogenase (Gapdh, PPM02946E) and 
osteopontin (Spp1, PPM03648C). Primers for low-density lipoprotein receptor (LDL-R, 
Mm00440169_m1) and 3-Hydroxy-3-Methylglutaryl-CoA Reductase (HMGCR, 
Mm1282494_g1) were obtained from Applied Biosystems (ThermoFisher. Foster City, 
CA). Relative gene expression of complimentary-DNA synthesized with the RT2 First 
Strand Kit (Qiagen) was evaluated on the Step-One-Plus, Real Time PCR system 
(Thermo Fisher Scientific. Waltham, MA) in comparison to Gapdh using the 2-ΔΔCT 
method [82]. 
Statistical Analysis: All data represent the mean of at least three individual experiments 
±SEM unless otherwise indicated.  Statistical analysis was performed using GraphPad 
Prizm software (San Diego, CA). Significance was determined by two-tailed student’s t-
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tests (2 groups) or ANOVA (>2groups) with Bonferroni’s correction. For all tests, p<0.05 




Selective Breeding Protocols Generate ATP-Lipid Transporter Deficient Mice: 
 Animals purchased from The Jackson Laboratory, were paired and the offspring 
subsequently genotyped using polymerase chain reaction utilizing the primer sets listed 
in Table 1. LysMCre wild-type and mutant reactions (Figure 1 A-B) were carried out 
independently due to non-specific primer binding. Representative images of agarose 
gels demonstrating homozygous wild-type (WT), heterozygous (HET) and homozygous 
mutant (MT) alleles for LyzMCre, ABCA1 and ABCG1 are shown in Figure 1. Animals 
homozygous for both LysMCre and ABCA1, ABCG1 or combined ABCA1/ABCG1 
mutant alleles were used to establish colonies. Animals were subsequently genotyped 
for 4 generations after the establishment of the colony to ensure unintended crosses 
were not included in experiments. 
Macrophage ABCG1 Deficiency Promotes Leukocyte Accumulation in the Lung: 
 To determine if macrophage deficiency of ABC-lipid transporters effects BAL cell 
count or composition, bronchoalveolar lavage (BAL) was performed. Previous reports 
have observed leukocyte infiltration in the lungs of complete ABCG1 knockouts (Wojak 
2008). Following BAL, the total cell count of C57Bl/6 (1.06x106 ± 0.05) and ABCA1-KO 
(1.01x106 ± 0.03) did not statistically differ (Figure 2A). The total cell count of ABCG1-
KO (1.31x106 ± 0.07) and ABCA1/ABCG1-DKO (1.67x106 ± 0.1) were significantly 
higher than wild-type animals (Figure 2A).  Wojcik et al. also demonstrated increased 
polymorphonuclear cells (PMNs) in the lungs of ABCG1 deficient animals [143]. 
Evaluation of BAL cell differentials from macrophage specific knockout mice found no 
difference in the leukocyte composition between C57Bl/6 and ABCA1-KO mice (Figure 
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2B). ABCG1-KO animals had a slight but significant increase in both lymphocytes and 
PMNs compared to wild-type animals (Figure 2B). ABCA1/ABCG1-DKO animals 
demonstrate further lymphocyte and PMN infiltration compared to C57Bl/6 and ABCG1-
KO animals (Figure 2B). 
Lipid Regulatory Genes are Dysregulated in ABC-Lipid Transporter Deficient 
Macrophages: 
 Macrophage intracellular lipid content is regulated by the complimentary effects 
of uptake, synthesis and subsequent export [31]. Lipid uptake and synthesis are 
mediated by the low-density lipoprotein receptor (LDL-R) and 3-Hydroxy-3-
Methylglutaryl-CoA (HMGCR) respectively while the export of lipids is facilitated by 
ABCA1 and ABCG1. Evaluation of LDL-R and HMGCR mRNA expression found a slight 
but non-significant decrease in ABCA1-KO, but significant downregulation in both 
ABCG1-KO and ABCA1/ABCG1-DKO alveolar macrophages (Figure 3). Interestingly, 
ABCG1 mRNA expression was significantly reduced in ABCA1-KO alveolar 
macrophages (Figure 3D). The expression of ABCA1 mRNA was significantly 
upregulated in ABCG1-KO alveolar macrophage (Figure 3C). 
Macrophage Deficiency of ABCG1 Promotes Pulmonary Lipid Accumulation: 
 To further characterize the extent of pulmonary lipid accumulation the diameter of 
alveolar macrophages and cholesterol content of BAL fluid was evaluated. The mean 
diameter of alveolar macrophages collected from C57Bl/6 (8.5 ± 0.3m) and ABCA1-KO 
(8.7 ± 0.2m) animals did not differ in size (Figure 4A). Alveolar macrophages of 
ABCG1-KO (9.7 ± 0.2m) and ABCA1/ABCG1-DKO (10.4 ± 0.1m) were significantly 
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larger than those from C57Bl/6 animals, no additional increase in size was observed in 
double knockout mice (Figure 4A). Extracellular cholesterol content was evaluated by 
measuring total cholesterol and cholesterol ester of BAL fluid. Total cholesterol content 
of C57Bl/6 animals (1.9 ± 0.1 g/mL) and ABCA1-KO (1.8 ± 0.1 g/mL) did not differ 
(Figure 4B). ABCG1-KO (2.3 ± 0.1 g/mL) and, to a further extent, ABCA1/ABCG1-DKO 
(2.9 ± 0.2 g/mL) BAL fluid demonstrate significantly higher total cholesterol content 
than C57Bl/6 animals (Figure 4A). BAL fluid cholesterol ester did not differ between 
C57Bl/6 (0.2 ± 0.04 g/mL) and ABCA1-KO (0.2 ± 0.03 g/mL) but was significantly 
increased in ABCG1-KO (0.5 ± 0.07 g/mL) and ABCA1/ABCG1-DKO (0.6 ± 0.04 
g/mL) animals (Figure 4C). No difference was observed between ABCG1-KO and 
ABCA1/ABCG1-double knockout animals. 
Macrophage ABCG1 deficiency promotes pro-inflammatory gene expression: 
 Lipid accumulation has been shown to promote pro-inflammatory macrophage 
activation. We evaluated the expression of the inflammatory cytokines chemokine (C-C 
motif) ligand-2 (CCL2) and osteopontin in BAL cells from ABC-lipid transporter 
knockouts. Interestingly, the expression of CCL2 and osteopontin were significantly 
decreased in alveolar macrophages isolated from ABCA1-KO animals compared to 
C57Bl/6 mice (Figure 5). BAL cells isolated from ABCG1-KO and to a further extent 
ABCA1/ABCG1-DKO demonstrate significantly higher CCL2 and osteopontin 




Here we describe the generation of ABCA1, ABCG1 and ABCA1/ABCG1 
macrophage specific knockout mice utilizing the Cre/lox system. We found ABCG1-KO 
and to a further extent ABCA1/ABCG1-DKO develop pulmonary lipid accumulation and 
alveolar macrophage expression of pro-inflammatory mediators. Interestingly, 
macrophage deficiency of ABCA1 did not affect pulmonary lipid accumulation at 8 
weeks of age. These studies suggest that alveolar macrophage ABCG1 and, to a 
further extent, the combined deficiency of ABCA1 and ABCG1 promotes pulmonary lipid 
accumulation. 
 Previous studies have suggested the deficiency of ABCG1 acts as the primary 
regulator of pulmonary lipid homeostasis. Lipid deposition is observed in ABCG1 
deficient mice as early as 3-weeks of age, while the earliest report in ABCA1 knockout 
animals is 4 months [19;143]. Wang et al. sought to quantify the contribution of 
macrophage ABCA1 and ABCG1 to cholesterol efflux. Those studies demonstrated that 
while ABCA1 deficiency reduced total cholesterol efflux, an alternative, compensatory 
pathway existed [136]. Further evaluation found eliminating both ABCA1 and ABCG1 
further decreased total cholesterol efflux potential, demonstrating these lipid 
transporters cooperatively mediate cholesterol efflux [136]. Although further studies will 
be required, the observation that combined deficiency of ABCA1 and ABCG1 
exacerbates pulmonary lipid accumulation suggest a similar mechanism takes place in 
the lung. 
 Previous studies have shown ABCG1 deficiency promotes pro-inflammatory lung 
inflammation. Evaluation of whole lung mRNA found increased expression of multiple 
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pro-inflammatory mediators including CCL2 [8]. Further evaluation of BAL fluid and 
alveolar macrophages from these animals found increased pro-inflammatory cytokines 
[143]. However, these studies did not evaluate alveolar macrophage CCL2 or 
osteopontin expression specifically. These observations further suggest that 






















Table 1: Polymerase chain reaction primers utilized for the identification of ATP-binding 




 Primer Sequence 5’ to 3’ 
 LyzMCre(Wild Type) TTACAGTCGGCCAGGCTGAC 
 LyzMCre (Common) CTTGGGCTGCCAGAATTTCTC 
 LyzMCre (Mutant) CCCAGAAATGCCAGATTACG 
 Abca1 (Forward) GATCTAGGCAGAAGGCACTTG 
 Abca1 (Reverse) TTTCCCAGAGATCCCTTTCA 
 Abcg1 (Forward) GTGGGGTGAGACATGTGGA 
 Abcg1 (Reverse) GGAAGAAGCCTTGGGTTGA 























Figure 1: Representative Image of PCR Gel Electrophoresis.  Following PCR 
amplification, genomic DNA was separated on 2% agarose gel and photographed under 
ultraviolet light.  Representative images of (A) LyzMCre-mutant and (B) LyzMCre wild-
type, (C) ABCA1 and (D) ABCG1 PCR products. Abbreviations: Homozygous wild-type 






























Figure 2: ABCG1 Deficiency Promotes Leukocyte Recruitment. (A) Total cell count 
and (B) leukocyte differentials of BAL cells isolated from naïve 8 week old mice. Data 


































B Leukocyte differentials of BAL cells isolated from 
naïve ABC-KO mice. ( n≥8/strain) 
   
AMs (%) L (%) PMN (%) 
 C57Bl/6J 
 Mean± SEM 99.6 ± 0.3 0.2 ± 0.1 0.2 ± 0.2 
 ABCA1-KO 
 Mean± SEM 99.7 ± 0.2 0.3 ± 0.2 0 
 ABCG1-KO 
 Mean± SEM  94.4 ± 1.0 1.5 ± 0.3 4.1 ± 1.0 
 A1/G1-DKO 
 Mean± SEM 87.6 ± 1.6 3.5 ± 0.8 9.5 ± 2.1 
  
 p<0.05, Knockout vs. C57Bl/6 
 
 p<0.05,  ABCA1/ABCG1-DKO vs ABCG1-KO 
 
Definition of abbreviations:  AMs, alveolar macrophages;  
















Figure 3: Lipid Regulatory Gene Expression in ABC-knockout Mice. Quantitative-
PCR analysis of (A) LDL-R and (B) HMGCR, (C) ABCA1 and (D) ABCG1 expression in 













































































































































































































Figure 4:  ABCG1 Deficiency Promotes Pulmonary Dyslipidemia.  (A) Mean 
diameter of alveolar macrophages determined from BAL cell cytospins.  (B) Total 
cholesterol and (C) cholesterol ester content of BAL fluid (BALF). Data represent mean 

























































































































































Figure 5: BAL cell Inflammatory Gene Expression of ABC-knockout Mice. 
Quantitative-PCR analysis of (A) CCL2 and (B) osteopontin expression in BAL cells 

















































































































ALVEOLAR MACROPHAGE ABCG1 DEFICIENCY PROMOTES GRANULOMA 





Pulmonary granuloma formation is a complex and poorly understood response to 
inhaled pathogens and particulate matter. To explore mechanisms of pulmonary 
granuloma formation and maintenance our laboratory has developed a multi-wall carbon 
nanotube (MWCNT) induced murine model of chronic granulomatous inflammation. We 
have demonstrated that the MWCNT model closely mimics pulmonary sarcoidosis 
pathophysiology, including the deficiency of alveolar macrophage ATP-binding cassette 
(ABC) lipid transporters ABCA1 and ABCG1. We hypothesized that deficiency of 
alveolar macrophage ABCA1 and ABCG1 would promote pulmonary granuloma 
formation and inflammation. To test this hypothesis, the effects of MWCNT instillation 
were evaluated in ABCA1, ABCG1 and ABCA1/ABCG1 macrophage-specific knockout 
mice. Histological examination found significantly larger pulmonary granulomas in 
ABCG1-KO and ABCA1/ABCG1 double knockout animals when compared to wild-type 
controls. Evaluation of bronchoalveolar lavage cells found increased expression of 
CCL2 and osteopontin, genes shown to be involved in the formation and maintenance 
of pulmonary granulomas. Deficiency of alveolar macrophage ABCA1 did not affect 
MWCNT induced granuloma formation or pro-inflammatory gene expression. These 
observations suggest that the deficiency of alveolar macrophage ABCG1 and, to a 





Sarcoidosis is a chronic inflammatory condition characterized by the presence of 
non-necrotizing granulomas. While any organ can be affected, the lungs and 
mediastinal lymph nodes are involved in more than 90% of clinical cases [23].  
Diagnosis is dependent on excluding the presence of infectious agents or previous 
exposure to materials known to produce granulomatous lesions. While the etiology of 
sarcoidosis remains unclear, current understanding suggests the presence of a poorly 
soluble antigen in genetically susceptible individuals. Epidemiological studies have 
found an association between the incidence of sarcoidosis and exposure to wood-
burning stoves, fireplaces and certain occupations, such as firefighting [68;75;114]. 
These environments contain particulate matter of respirable sizes, particularly carbon 
nanotubes. 
Carbon nanotubes are produced as the byproducts of combustion or 
manufactured for use in industrial processes. These materials may also have adverse 
implications for human health. Assessing the respiratory toxicology of carbon 
nanomaterials, Lam et al. observed granulomatous like lesions in the lungs of exposed 
animals [79]. These observations prompted our laboratory to investigate the use of 
multiwall carbon nanotubes (MWCNT) to generate a murine model of pulmonary 
sarcoidosis [58]. Our previous studies have shown that the MWCNT model bears 
striking similarities to sarcoidosis pathophysiology, including increased expression of 
pro-inflammatory mediators and decreased expression of alveolar macrophage ATP-
binding cassette (ABC) lipid transporters ABCA1 and ABCG1 [16]. 
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ABCA1 and ABCG1 facilitate the transfer of lipids across plasma membranes 
and play an important role in the catabolism of pulmonary surfactant. Deficiency of 
either ABCA1 or ABCG1 has been found to promote pulmonary lipid accumulation 
[11;19]. Intracellular lipid accumulation has been shown to promote pro-inflammatory 
macrophage activation [147]. Clinically, deficiency of lipid transporters have been 
observed in Tangiers disease (ABCA1) and pulmonary alveolar proteinosis (ABCG1). 
These pathologies are characterized by dysregulated lipid homeostasis and increased 
inflammatory mediators [26;131]. Upregulation of alveolar macrophage ABCG1 in a 
murine model of alveolar proteinosis has been shown to reduce pulmonary lipid 
accumulation and to improve lung function [87]. 
These observations suggest the lipid transporters ABCA1 and ABCG1 may play 
a significant role in pulmonary granulomatous inflammation. To further address this 
question we utilized macrophage-specific knockout (KO) mice, deficient in ABCA1, 
ABCG1 or both ABCA1 and ABCG1. We hypothesized that deficiency of the ABC-lipid 
transporters would exacerbate MWCNT induced granulomatous inflammation. 
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MATERIALS AND METHODS 
 
Mice: All studies were conducted in accordance with the National Institutes of 
Health guide for the use of laboratory animals and approved by the East Carolina 
University Institutional Animal Care and Use Committee. C57Bl/6J wild-type mice were 
obtained from The Jackson Laboratory (Bar Harbor, ME). Generation of macrophage-
specific ATP-binding cassette (ABC) lipid transporter knockout mice are described in 
Chapter 2. The instillation of multiwall carbon nanotubes (MWCNT) was performed as 
described previously [58]. Briefly, MWCNT were suspended in 35% Infasurf/phosphate 
buffered saline (vehicle) solution by ultrasonification. Animals were anesthetized using 
isoflorane, suspended by their incisors and oropharyngeally instilled with 50µL of 
vehicle or 100µg of MWCNT. 
Tissue Collection: Animals were euthanized by intraperitoneal injection of 
tribromoethanol. Bronchoalveolar lavage (BAL) was performed by cannulating the 
trachea and sequentially lavaging the whole lung with 1mL aliquots of 0.2% 
lidocaine/PBS solution totaling 5mL as previously described [88]. Following 
centrifugation (1800 RPM x 10 minutes, 4°C), supernatant was snap frozen on dry ice 
as BAL fluid (BALF).  BAL cells were washed twice in 4mL chilled PBS and snap frozen 
as a pellet for further analysis. Differential cell counts were determined from BAL cell 
cytospins, generated by centrifugation at 500 RPM x 5 minutes and subsequently 
stained with Diff Quick solution (Thermo Fisher Scientific. Waltham, MA). Histological 
analysis was performed on paraffin sections of whole lungs which had been inflated with 
300µL 10% buffered formalin solution as previously described [58]. 
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RNA Purification and Analysis:  Total RNA was collected using the miRNeasy 
Micro Kit (Qiagen. Hilden, Germany) according to the manufacturer’s protocol. Specific 
primers were obtained from Qiagen for ATP binding cassette (ABC) transporter-A1 
(Abca1, PPM03952F), Abcg1 (PPM03895A), chemokine (C-C motif) ligand-2 (Ccl2, 
PPM03151G), Glyceraldehyde-3-phosphate-dehydrogenase (Gapdh, PPM02946E), 
osteopontin (Spp1, PPM03648C) platelet derived growth factor, alpha (Pdgfa, 
PPM03103E) and transforming growth factor, beta 1 (Tgfb1, PPM02991B). Relative 
gene expression of complimentary DNA synthesized with the RT2 First Strand Kit 
(Qiagen. Hilden, Germany) was evaluated on the StepOnePlus PCR system (Thermo 
Fisher Scientific. Waltham, MA) in comparison to Gapdh using the 2-ΔΔCT method [82]. 
Analysis of Bronchoalveolar Lavage Fluid: Total cholesterol content was 
measured using the Amplex Red Cholesterol Assay kit (Thermo Fisher Scientific. 
Waltham, MA) according to manufacturer’s instructions in the presence of cholesterol 
esterase. The concentration of platelet derived growth factor subunit a (PDGFα) was 
determined using RayBio® Mouse PDGF-AA ELISA Kit (RayBioTech, cat# ELM-
PDGFAA. Norcross, GA.) according to the manufacturer’s instructions. The 
concentration of transforming growth factor beta (TGFβ) was determined using the 
LEGEND MAX Total TGF-β1 ELISA Kit (BioLegend, cat#436707. San Diego, CA) 
according to the manufacturer’s instructions. 
Histological Assessment: Following fixation, entire mouse lungs were embedded 
in paraffin. Five-micron thick sections were stained with hematoxylin & eosin (H&E) or 
Gomori’s trichrome. Quantitative analysis of granulomas were performed on digital 
images of H&E stained whole lung sections acquired on an Aperio ScanScope (Aperio 
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Technologies, Inc. Vista, CA).  Analysis was performed blindly on randomized digital 
images, scanning the entire lung at 20X magnification for pulmonary granulomas. A 
granuloma was defined as a carbon aggregate completely surrounded by tissue and 
associated with three or more cell nuclei. Pulmonary fibrosis scoring was performed 
using modified Ashcroft method [57] and represents the mean score of 40 randomly 
chosen fields (X200 magnification) across the entire lung. The length (L) and width (W) 
of the tracheobronchal lymph node, identified based on Van den Broeck et al. [133], 
was used to determine lymph node volume using the formula (LxW2)π/6. Carbon 
content of alveolar macrophages was determined by evaluating alveolar macrophages 
on BAL cytospins described above under 400X magnification. 
Phagocytosis Assay:  Phagocytic ability of alveolar macrophages was evaluated 
using the pHrodo BioParticles Phagocytosis Flow Cytometry Kit (Thermo Fisher 
Scientific. Waltham, MA) according to manufacturer’s protocol.  The identification of 
alveolar macrophages was facilitated by counterstaining the cells with anti-CD11c. 
Alveolar macrophages were defined as CD11c+ cells. 
Statistical Analysis: All data represent the mean of at least three individual 
experiments ±SEM unless otherwise indicated. Statistical analysis was performed using 
Graph Pad Prism software (San Diego, CA). Significance was determined by using 
unpaired Student’s t-test (2 groups) or ANOVA (>2 groups) followed by Bonferroni 




Macrophage ABCG1 Deficiency Promotes Pulmonary Granuloma Formation 
To evaluate the effects of alveolar macrophage lipid transporter deficiency on 
pulmonary granuloma formation, macrophage-specific ABCA1, ABCG1 or 
ABCA1/ABCG1 double knockout mice were utilized.  Animals were evaluated 60 days 
following instillation of vehicle (35% surfactant) or 100g of MWCNT. Wild-type C57Bl/6 
and ABCA1-KO animals instilled with vehicle were histologically indistinguishable 
(Figure 1). Vehicle instilled ABCG1-KO or ABCA1/ABCG1-DKO mice however exhibited 
a marked increase of lipid loaded alveolar macrophages within the airways. These 
observations are similar to previous observations in ABCG1 deficient animals [11]. 
Following MWCNT instillation, pulmonary granulomas in C57Bl/6 and ABCA1-KO mice 
typically consisted of a carbon aggregate core surrounded by epithelioid macrophages 
(Figure 1). Granulomas in ABCG1-KO and ABCA1/ABCG1-DKO animals were 
noticeably different, generally consisting of multiple carbon aggregates and irregular 
boarders of epithelioid macrophages.  Representative images are shown in Figure 1. 
Granulomatous inflammation was further characterized by determining the 
average number and size of MWCNT induced lesions from digital images of H&E 
stained lung sections. Our analysis found the average number of granulomas per whole 
lung section was similar between ABC-lipid transporter knockouts and wild-type animals 
(Figure 2A).  Evaluation of mean granuloma size found a slight, but non-significant 
increase in ABCA1-KO granulomas (Figure 2B). MWCNT induced granulomas 
observed in ABCG1-KO and ABCA1/ABCG1-DKO animals however were found to be 
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35% and 39% larger, respectively, than those observed in wild-type controls (Figure 
2B). 
Macrophage ABCG1 Deficiency Promotes Alveolar Macrophage Inflammatory Gene 
Expression.  
To determine if the alveolar cell population was affected by MWCNT, 
bronchoalveolar lavage (BAL) was performed 60 days following instillation. Wild-type 
and ABCA1-KO BAL consisted of approximately 1.0x106 leukocytes and were 
predominately alveolar macrophages, (>97%) (Figure 3).  ABCG1-KO and 
ABCA1/ABCG1-DKO had twice as many isolated leukocytes, (~2.0x106 ), compared to 
wild-type animals and, as previously observed [143], included increased 
polymorphonuclear cells, (9-16%) (Figure 3B). The total cell count nor composition of 
leukocytes in the lavage were affected by the instillation of MWCNT when compared to 
vehicle instilled animals (Figure 3). 
Previous studies have found the pro-inflammatory mediators (C-C motif) ligand-2 
(CCL2) and osteopontin play a critical role in the formation of pulmonary granulomas 
[83;104]. Our laboratory has also reported the upregulation of these genes in BAL cells 
isolated from MWCNT instilled wild-type animals [15;59]. The data reported here are 
similar to those observations. The deficiency of ABCA1 did not promote CCL2 or 
osteopontin expression following MWCNT instillation (Figure 4). Vehicle-instilled 
ABCG1-KO animals exhibited significantly higher CCL2 and osteopontin expression 
compared to wild-type animals, and this increase was further exacerbated by the 
instillation of MWCNT (Figure 4). Interestingly, BAL cells of vehicle-instilled 
ABCA1/ABCG1-DKO animals demonstrated significantly higher CCL2 and osteopontin 
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expression than ABCG1-KO, but had no additional increase of these genes following 
MWCNT instillation (Figure 4). 
ABCG1 Deficiency Promotes MWCNT Induced Fibrosis and Pro-Fibrotic Mediators 
The progression of pulmonary sarcoidosis is frequently characterized by the 
development of fibrosis. MWCNT induced fibrosis was evaluated from whole lung 
sections following Gomori trichrome staining. We have previously reported that the 
MWCNT induced granulomas of wild-type animals do not consistently demonstrate 
collagen deposition [58]. Here we sought to increase the sensitivity of our analysis by 
evaluating the entire lung. Using this method, we found that MWCNT instilled wild-type 
animals have increased fibrosis compared to those receiving vehicle alone (Figure 5A). 
MWCNT instilled ABCA1-KO animals demonstrate a similar increase in fibrosis score 
compared to wild-type animals (Figure 5A). ABCG1-KO and ABCA1/ABCG1-DKO 
animals instilled with vehicle demonstrate a significantly higher fibrosis score than wild-
type animals, and this increase was further exacerbated by the instillation of MWCNT 
(Figure 5A). MWCNT induced fibrosis in both ABCG1-KO and ABCA1/ABCG1-DKO 
mice was significantly greater than that observed in wild-type animals. 
To further examine fibrotic changes, we evaluated alveolar macrophage gene 
expression and BAL fluid protein concentration of the pro-fibrotic mediators’ platelet 
derived growth factor-α (PDGFα) and transforming growth factor-β (TGFβ). We found 
that BAL cells from wild-type and ABCA1-KO animals demonstrate a similar increase in 
PDGFα expression following MWCNT instillation (Figure 5B). Vehicle-instilled ABCG1-
KO and ABCA1/ABCG1-DKO BAL cells had significantly higher PDGFα mRNA 
expression than wild-type animals, and demonstrate a further increase following 
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MWCNT instillation (Figure 5B). The combined deficiency of ABCA1/ABCG1 did not 
further promote BAL cell PDGFα expression. Evaluation of BAL cell TGFβ expression 
found no difference between vehicle instilled wild-type or ABC-lipid transporter knockout 
animals (Figure 5C). Following MWCNT instillation we observed a slight increase of 
TGFβ expression in BAL cells of ABCG1-KO (1.2 ± 0.2 fold) and ABCA1/ABCG1-DKO 
(1.2 ± 0.1 fold)  animals compared with vehicle instilled controls (Figure 5C). TGFβ 
expression did not statistically differ between MWCNT instilled wild-type, ABCG1-KO or 
ABCA1/ABCG1-DKO animals. 
Further evaluation of BAL fluid PDGFα protein concentration found no significant 
difference between vehicle instilled wild-type (64.6±13.2 pg/mL), ABCA1-KO (42.6±10.2 
pg/mL), ABCG1-KO (71.1±7.2 pg/mL) or ABCA1/ABCG1-DKO (57.4±2.0 pg/mL) 
animals. Following MWCNT instillation, BAL fluid PDGFα concentration was elevated in 
wild-type (104.6±11.6 pg/mL, p=0.06), ABCA1-KO (89.6±8.9 pg/mL), ABCG1-KO 
(116.1±8.1 pg/mL) and ABCA1/ABCG1-DKO animals (135.4±20.3 pg/mL) animals 
(Figure 5D). BAL fluid PDGFα protein concentration did not statistically differ between 
MWCNT instilled wild-type and ABC-lipid transporter knockout animals. BAL fluid TGFβ 
protein concentrations of vehicle instilled wild-type (31.0±1.9 pg/mL) and ABCA1-KO 
(27.5±1.8 pg/mL) animals were not statistically different. However, in contrast to BAL 
cell gene expression, TGFβ protein concentration of the BAL fluid was significantly 
higher in ABCG1-KO (349.5±58.9 pg/mL) and ABCA1/ABCG1-DKO (348.9±39.7 pg/mL) 
animals when compared to wild-type mice (Figure 5E). Following MWCNT instillation, 
we observed a slight increase of TGFβ protein concentration in wild-type (85.6±16.6 
pg/mL) and ABCA1-KO (73.1±34.0 pg/mL) animals (Figure 5E). MWCNT instilled 
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ABCG1-KO (304.1±46.6 pg/mL) and ABCA1/ABCG1-DKO (341.9±36.7 pg/mL) animals 
demonstrated constitutively higher TGFβ protein content than wild-type animals, but 
were not statistically different from vehicle instilled controls (Figure 5E). 
Instillation of MWCNT Differentially Regulates the Expression of Lipid Transporters 
The effects of MWCNT instillation were evaluated on the expression of the 
remaining lipid transporter in single-knockout animals. ABCG1-mRNA was reduced in 
ABCA1-KO animals following MWCNT instillation, similar to changes observed in wild-
type mice [16], (Figure 6A). In contrast, MWCNT instillation increased the expression of 
ABCA1-mRNA in ABCG1-KO animals (Figure 6B). Changes in pulmonary lipid 
composition were evaluated by measuring the total cholesterol content of the BAL fluid. 
We found BAL fluid cholesterol concentration of vehicle-instilled wild-type (1.6 ± 
0.1g/mL) and ABCA1-KO (1.5 ± 0.1g/mL) animals did not differ, however ABCG1-KO 
(2.9 ± 0.3g/mL) and ABCA1/ABCG1-DKO (4.6 ± 0.6g/mL) animals showed 
progressive lipid accumulation in the lungs (Figure 7). Following MWCNT instillation, 
BAL fluid cholesterol was significantly increased in wild-type (2.3 ± 0.2g/mL) and 
ABCA1-KO mice (2.4 ± 0.4g/mL). The increased BAL fluid cholesterol content 
observed in ABCG1-KO (3.5 ± 0.3g/mL) or ABCA1/ABCG1-DKO (6.0 ± 1.0g/mL) 
mice failed to reach significance compared to vehicle controls, but were significantly 





ABC-Lipid Transporter Deficient Alveolar Macrophages have Increased Carbon Content 
and Phagocytic Capacity 
The observations that ABCG1 deficiency promotes alveolar macrophage 
activation and MWCNT induced granulomatous inflammation prompted us to further 
investigate how these cells phagocytose carbon nanoparticles. We hypothesized that 
ABCG1 deficiency would lead to a greater number of carbon containing alveolar 
macrophages. To test this hypothesis, alveolar macrophages were evaluated from BAL 
cell cytospins for the presence or absence of intracellular carbon. We found that the 
percentage of alveolar macrophages containing carbon were significantly higher in each 
ABC-lipid transporter knockout: ABCA1-KO (26 ± 3.4%), ABCG1-KO (22 ± 2.2%) and 
ABCA1/ABCG1-DKOs (22 ± 1.5%) compared to wild-type (14 ± 1.4%) animals (Figure 
8). While no significant difference was observed among ABCA1, ABCG1 or 
ABCA1/ABCG1 knockouts, the increased percentage of ABCA1-KO macrophages 
containing carbon was unexpected. 
To further define the phagocytic capacity of ABC-lipid transporter deficient 
alveolar macrophages, BAL cells were incubated with pH-sensitive fluorescently labeled 
E.coli particles and evaluated by flow cytometry (Figure 9). The percentage of alveolar 
macrophages which phagocytized labeled particles was increased in ABCA1-KO (35 ± 
1.9%) and to a further extent, in ABCG1-KO (55 ± 2.5%) and ABCA1/ABCG1-DKO (51 
± 2.6%), compared to wild-type (24 ± 4.2%) animals (Figure 9B). Mean florescent 
intensity, a measure of the number of particles phagocytosed per macrophage, was 
significantly increased in ABCG1-KO and ABCA1/ABCG1-DKO animals, but not 
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ABCA1-KO (Figure 9D).  These data agree with a previous report which found that 
ABCG1 deficient macrophages had an increased capacity to clear apoptotic cells [143].  
MWCNT Induced Mediastinal Lymphadenopathy is Exacerbated by the Deficiency of 
ABC-Lipid Transporters. 
Mediastinal and hilar lymph node involvement are defining characteristics of 
pulmonary sarcoidosis. Previous studies have shown the ability of intra-tracheally 
instilled MWCNT to translocate to lung associated lymph nodes [2]. We sought to 
characterize the change in mediastinal lymph node volume in wild type and ABC-lipid 
transporter deficient animals following MWCNT instillation. The lymph node volume of 
vehicle-instilled wild-type (1.8 ± 0.2 mm3) and ABCA1-KO (2.0 ± 0.2 mm3) animals did 
not statistically differ; however ABCG1-KO (6.6 ± 0.9 mm3) and ABCA1/ABCG1-DKO 
(10.6 ± 1.2 mm3) animals had a significant increase in lymph node volume. Following 
MWCNT instillation, mediastinal lymph node volume was significantly increased in wild-
type (4.8 ± 0.4 mm3), ABCA1-KO (5.5 ± 0.7 mm3), ABCG1-KO (9.7 ± 0.9 mm3) and 
ABCA1/ABCG1-DKO (15.5 ± 1.2 mm3) compared to vehicle-instilled controls. The 
MWCNT induced mediastinal lymphadenopathy observed in ABCG1-KO and 




We have previously described a MWCNT induced model of chronic 
granulomatous inflammation which bears striking similarity to pulmonary sarcoidosis, 
including the deficiency of alveolar macrophage lipid transporters ABCA1 and ABCG1 
[16;58]. The deficiency of these genes correlate with pulmonary lipid accumulation and 
increased expression of pro-inflammatory mediators in the MWCNT model [13;16]. 
While the deficiency of ABCA1 or ABCG1 has been shown to promote pulmonary lipid 
accumulation [10;19], the involvement of these transporters in chronic granulomatous 
lung disease remains unclear. These studies aimed to determine if the deficiency of 
ABCA1 or ABCG1 contributes to pulmonary granuloma formation and inflammation. 
Here we report that deficiency of alveolar macrophage ABCG1, but not ABCA1, 
promotes MWCNT induced pulmonary granuloma formation, pulmonary fibrosis, pro-
fibrotic mediators and the expression of CCL2 and osteopontin. These observations 
suggest that alveolar macrophage ABCG1 acts as a negative regulator of pulmonary 
granulomatous inflammation. 
The pro-inflammatory mediators CCL2 and osteopontin are upregulated in 
granulomatous tissue of pulmonary sarcoidosis patients and wild-type animals bearing 
MWCNT induced granulomas [15;59;108]. Deficiency of these genes in murine studies 
has been shown to prevent the formation of pulmonary granulomas in response to 
stimuli [83;104], suggesting that these mediators play an integral role in the process. 
ABCG1 deficiency has been shown to promote pulmonary inflammation, including 
increased expression of CCL2 in lung tissue of total knockout animals [8]. To our 
knowledge, the expression of osteopontin has not been evaluated in the lungs of lipid 
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transporter deficient mice. Evaluation of CCL2 and osteopontin found intrinsic elevation 
of these mediators in in alveolar macrophages deficient of ABCG1 and further 
upregulation following MWCNT instillation. The increased expression of these mediators 
in ABCG1 or ABCA1/ABCG1 macrophage-specific knockout animals likely promotes 
MWCNT induced granuloma formation. 
Here we report that deficiency of alveolar macrophage ABCG1 or the combined 
deficiency of ABCA1/ABCG1, promotes MWCNT induced lymphadenopathy, pulmonary 
fibrosis and the pro-fibrotic mediators PDGFα and TGFβ. These observations correlate 
with the progressive pulmonary lipid accumulation noted in these animals. Previous 
studies have reported lipid loaded macrophages in patients suffering from fibrotic lung 
disease and in animal models of pulmonary fibrosis [5;17;54;145]. Transcriptome 
analysis of lipid loaded macrophages isolated from subcutaneous granulomas revealed 
increased expression of pro-fibrotic pathways [130]. Furthermore, Romero et al. have 
demonstrated that deficiency of ABCG1, in part due to pulmonary lipidosis, promotes 
bleomycin induced lung fibrosis [118]. These observations further suggest a link 
between dysregulated pulmonary lipid homeostasis and the progression of lung 
diseases. 
In an effort to better describe how ABC-lipid transporter deficient alveolar 
macrophages respond to carbon nanoparticles, we evaluated the carbon content and 
phagocytic capacity of these cells. We found an increased number of ABCA1, ABCG1 
and ABCA1/ABCG1 deficient macrophages contain carbon compared to wild-type 
animals. Further studies demonstrate that the phagocytic ability of these cells increases 
in the order of: ABCA1/ABCG1-DKO ≈ ABCG1-KO > ABCA1-KO > C57/Bl6 (wild-type). 
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The increased number of carbon laden macrophages in ABCA1-KO BAL was 
unexpected. Given the increased total BAL cell count observed in the ABCG1 and 
ABCA1/ABCG1-DKO animals, it may be inferred that the macrophage-carbon ratio is 
decreased in these animals, explaining the relatively equal number of carbon containing 
macrophages in ABCA1-KO animals. While these studies do not account for unique 
mechanisms of E.coli and carbon nanotube phagocytosis, the observations suggest 
macrophage deficiency of ABCG1 or combined ABCA1/ABCG1 may promote carbon 
nanotube phagocytosis and retention in the lung, increasing pulmonary toxicity. 
An unexpected observation made during the course of these studies was the 
absence of a significant increase in pro-inflammatory mediators in ABCA1-KO. Previous 
reports have found progressive pulmonary lipid accumulation in complete ABCA1-KO 
animals [19;90], but at a slower rate than observed in ABCG1 deficient animals. The 
absence of significant pulmonary lipid accumulation may explain the lack of an 
inflammatory phenotype. Previous studies have also indicated that the inflammatory 
potential of ABCA1 deficient macrophages is less than those deficient of ABCG1 or 
ABCA1/ABCG1. Following lipopolysaccharide (LPS) stimulation, peritoneal 
macrophages of ABCA1 deficient mice showed only a slight increase in a limited subset 
of inflammatory cytokines compared to ABCG1 or, to a greater extent, ABCA1/ABCG1-
double knockout cells [147].  
In conclusion, our studies indicate that alveolar macrophage ABCG1 is a crucial 
regulator of pulmonary granuloma formation and inflammation. Our laboratory has 
demonstrated that the MWCNT model closely mimics sarcoidosis pathophysiology. The 
progressive stages of pulmonary sarcoidosis are characterized by hilar node 
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involvement, granulomatous infiltrates into the lungs and finally end stage pulmonary 
fibrosis [137]. Here we demonstrate that the deficiency of alveolar macrophage ABCG1 
exacerbates each of these clinical parameters. We have recently demonstrated that 
increased alveolar macrophage ABCG1 expression and inhibition of pulmonary lipid 
accumulation correlate with reduced MWCNT induced pulmonary granuloma formation 
[91]. These observations together with those from the current study suggest that 




















Figure 1: Representative Images or MWCNT Induced Granulomas. Representative 
images of C57Bl/6, ABCA1-KO, ABCG1-KO and ABCA1/ABCG1-DKO animals instilled 


















Figure 2: ABCG1 Deficiency Exacerbates the Size of Pulmonary Granulomatous 
Lesions. Quantitative analysis of the (A) number and (B) size of MWCNT induced 
granulomatous lesions observed from H&E stained lung tissue. Data represent mean ± 



































































































Figure 3: Macrophage ABCG1 Deficiency Promotes Inflammatory Cell 
Recruitment. (A) Total cell count and (B) differential cell counts of BAL 60 days 





































































Strain/Treatment AMs (%) L (%) PMN (%) 
C57Bl/6 
      Vehicle,   n=11: 98.9±0.3 1.1±0.3 0 
      MWCNT, n=11: 99.6±0.4 1.1±0.4 0 
ABCA1-KO  
       Vehicle,   n=9: 99.9±0.1 0.1±0.1 0 
       MWCNT, n=9: 97.3±0.7 0.7±0.3 2.3±0.7 
ABCG1-KO 
      Vehicle,   n=8: 89.5±2.2 1.8±0.5 8.9±1.7 
      MWCNT, n=11: 89.8±1.5 1.0±0.4 9.5±1.3 
A1/G1-DKO 
      Vehicle,   n=16: 85.1±1.9 1.9±0.5 13.1±1.5 
      MWCNT, n=18: 82.8±1.6 1.5±0.4 15.9±1.4 
Definition of abbreviations:  AMs: Alveolar Macrophage,  
L: Lymphocytes, PMN: Polymorphonuclear cell.  p<0.05 
















Figure 4: Macrophage ABCG1 Deficiency Promotes Pro-Inflammatory Gene 
expression.  Quantitative-PCR analysis of (A) CCL2 and (B) osteopontin expression in 











































































































n   4 per treatment
 p < 0.05, C57 vs KO VEHICLE
 p < 0.05, C57-MW vs KO-MW















Figure 5: Deficiency of ABCG1 Promotes Pulmonary Fibrosis. (A) Modified Ashcroft 
scoring of vehicle or MWCNT instilled whole lung sections. (B) qRT-PCR analysis of 
PDGFα expression in alveolar macrophages of vehicle or MWCNT instilled mice (p < 
0.05, C57-SHAM vs KO-SHAM;  p < 0.05, SHAM vs MWCNT/Strain;  p < 0.05, 
C57-MW vs KO-MW, n≥4/treatment). The concentration of BAL fluid (C) PDGFα, (D) 










































































































































































































































































Figure 6: Instillation of MWCNT affects ABC-Lipid Transporter Expression.  
Quantitative-PCR analysis of (A) ABCG1 expression in ABCA1-KO animals and ABCA1 
expression in ABCG1-KO animals 60 days following instillation of vehicle or MWCNT. 































































































 = p< 0.05 compared to C57 vehicle
 = p< 0.05 vehicle vs MWCNT/strain

















Figure 7: Pulmonary Lipid Accumulation is elevated in ABCG1 and 
ABCA1/ABCG1 deficient animals. Total cholesterol content of BAL fluid 60 days 
























































































Figure 8: Percentage of Alveolar Macrophages Containing MWCNT. Alveolar 
macrophages of wild type or ABC-knockout mice were visualized on BAL cell cytospins 






































































Figure 9: Phagocytic Capacity of Lipid Transporter Deficient Alveolar 
Macrophages. (A) Representative contour plots of flow cytometry data. (B) Percent 
alveolar macrophage population to phagocytose fluorescently labeled E.coli particle. (C) 
Representative mean florescent intensity per alveolar macrophage. (D) Mean florescent 





















































































































































Figure 10:  MWCNT Induced Lymphadenopathy is Exacerbated by the Deficiency 
of ABCG1. Mediastinal lymph node volume was determined from mice 60 days 

































































































PPAR-GAMMA PATHWAYS ATTENUATE PULMNARY GRANULOMA FORMATION 
IN A CARBON NANOTUBE INDUCED MURINE MODEL OF SARCOIDOSIS
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ABSTRACT 
Peroxisome proliferator activated receptor gamma (PPAR), a ligand activated 
nuclear transcription factor, is constitutively expressed in alveolar macrophages of 
healthy individuals.  PPAR deficiencies have been noted in several lung diseases 
including the alveolar macrophages of pulmonary sarcoidosis patients.  We have 
previously described a murine model of multiwall carbon nanotube (MWCNT) induced 
pulmonary granulomatous inflammation which bears striking similarities to pulmonary 
sarcoidosis, including the deficiency of alveolar macrophage PPAR.  Further studies 
demonstrate alveolar macrophage PPAR deficiency exacerbates MWCNT induced 
pulmonary granulomas.  Based on these observations we hypothesized that activation 
of PPAR via administration of the PPAR-specific ligand rosiglitazone would limit 
MWCNT induced granuloma formation and promote PPAR-dependent pathways.  
Results presented here show that rosiglitazone significantly limits the frequency and 
severity of MWCNT induced pulmonary granulomas.  Furthermore, rosiglitazone 
attenuates alveolar macrophage NF-κB activity and downregulates the expression of 
the pro-inflammatory mediators, CCL2 and osteopontin.  PPAR activation via 
rosiglitazone also prevents the MWCNT induced deficiency of PPAR-regulated ATP-
binding cassette lipid transporter-G1 (ABCG1) expression.  ABCG1 is crucial to 
pulmonary lipid homeostasis.  ABCG1 deficiency results in lipid accumulation which 
promotes pro-inflammatory macrophage activation.  Our results indicate that restoration 
of homeostatic ABCG1 levels by rosiglitazone correlates with both reduced pulmonary 
lipid accumulation, and decreased alveolar macrophage activation.  These data confirm 
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and further support our previous observations that PPAR pathways are critical in 




Granulomatous lung diseases represent a significant health burden worldwide.  
Sarcoidosis is an inflammatory condition characterized by the presence of non-
necrotizing granulomas which effects the lungs and mediastinal lymph nodes in 90% of 
clinical cases [23]. The etiology of sarcoidosis has not been determined, however 
current understanding suggest the presence of a poorly soluble antigen leading to an 
exuberant host immune response in genetically susceptible individuals [32]. 
Epidemiological studies have found a correlation between pulmonary sarcoidosis and 
exposure to wood-burning stoves, fireplaces and certain occupations such as 
firefighters [68;75;114]. An increased incidence of sarcoid-like granulomatous lesions 
have also been reported in first responders present at the September 2001 World Trade 
Center Disaster [65]. These environments have been shown to contain particulate 
matter of respirable sizes, including carbon nanotubes.  Carbon nanotubes (CNT) are 
produced as byproducts of combustion or manufactured for a variety of commercial 
applications. Evaluation of the respiratory toxicology of these materials has found the 
potential to induce pulmonary granulomatous lesions in exposed animals [79;96]. These 
observations prompted our laboratory to investigate the use of multiwall carbon 
nanotubes (MWCNT) to generate a murine model of pulmonary granulomatous 
inflammation to study pulmonary sarcoidosis [58]. 
 Previous methods utilized to induce pulmonary granulomas included the 
administration of pathogens or introduction of antigen bound sepharose beads into the 
tail vein of sensitized animals [33;63;76]. While these models have advanced our 
understanding of pulmonary granuloma formation they have notable drawbacks 
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including the presence of active pathogens, eliciting granuloma in the pulmonary 
capillaries instead of the airways and a relatively short resolution time. In our studies, 
evaluation of mice 60 days following MWCNT instillation found the persistence of 
granulomatous lesions throughout the lung [58]. Further studies demonstrated that the 
MWCNT model closely mimics sarcoidosis pathophysiology, including elevated 
expression of inflammatory mediators and reduced expression and activity of alveolar 
macrophage peroxisome proliferator-activated receptor gamma (PPAR) [58;59;95]. 
PPAR, a ligand-activated nuclear transcription factor, has been shown to limit 
pro-inflammatory macrophage activation [117].  PPAR regulates gene expression by 
selectively binding PPAR-response elements, promoting target gene expression, or 
through the inhibition of other transcription factors such as nuclear factor-κB (NF-κB) 
[47;115]. PPAR, constitutively active in alveolar macrophages of healthy individuals, is 
deficient in multiple lung diseases including alveolar macrophages of pulmonary 
sarcoidosis patients [27;35;73]. The importance of alveolar macrophage PPAR to 
pulmonary homeostasis is demonstrated by macrophage-specific PPAR knockout 
mice. These animals exhibit increased Th-1 pro-inflammatory cytokine expression and 
dysregulated pulmonary lipid catabolism [7;88]. 
PPAR maintains pulmonary lipid homeostasis through the expression of alveolar 
macrophage ATP-binding cassette lipid transporter-G1 (ABCG1) [6;7]. Following uptake 
by scavenger receptors, such as the PPAR-regulated cluster of differentiation-36 
(CD36), lipids are catabolized and effluxed to extracellular acceptors by ABCG1, and 
the complimentary lipid transporter ABCA1 [109]. Deficiency of ABCG1 or ABCA1 
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results in pulmonary lipid accumulation and elevated inflammatory mediators 
[8;19;74;143]. The inability to properly efflux cholesterol leads to increased sensitivity to 
extracellular inflammatory signaling in ABCA1/ABCG1 deficient macrophages [147]. Our 
recent studies in alveolar macrophages from sarcoidosis patients and MWCNT instilled 
mice observed decreased expression of both ABCG1 and ABCA1 [16].  The deficiency 
of these lipid transporters correlates with increased alveolar macrophage lipid 
accumulation in MWCNT instilled animals [16].   
These observations suggest that downregulation of ABCG1 and ABCA1 may 
contribute to MWCNT induced inflammation. We hypothesized that increase of the 
PPAR-ABCG1 pathway would limit alveolar macrophage activation and pulmonary 
granuloma formation. To address this hypothesis we utilized the PPAR-specific agonist 
rosiglitazone to activate PPAR pathways. Results shown here indicate that 
rosiglitazone attenuates MWCNT induced granulomatous inflammation. 
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MATERIALS AND METHODS 
Animal care and treatment: Animal studies were conducted in accordance with 
the National Institutes of Health guide for the care and use of Laboratory animals and 
with approval from the East Carolina University Institutional Animal Care and Use 
Committee.  C57BL/6J wild type mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME).  An equal number of age and sex matched controls were randomly 
assigned into experimental groups.  Rosiglitazone laden diets were produced by Teklad 
Diets (Madison, MI), incorporating rosiglitazone (Cayman Chemical. Ann Arbor, MI) into 
standard rodent chow (Prolab RMH 300, LabDiet; St. Louis, MO), delivering 2, 6 or 
12mg/kg/day (TD.160572, TD.160573 and TD.160574 respectively).  Diets were 
administered daily, three days prior to instillation of multiwall carbon nanotubes 
(MWCNT) until necropsy at the indicated time point. 
MWCNT Model: Pulmonary granulomas were generated by oropharyngeal 
aspiration of 100g MWCNT (Cat.900-1501, Lot: GS1801) purchased from SES 
Research, Houston Texas as previously described [58]. Animals were euthanized with 
tribromoethanol and bronchoalveolar lavage (BAL) was performed for the collection of 
BAL cells as previously described [88].  Differential counts were performed on cytospins 
stained with modified Wright’s stain.  Histological analysis was performed on un-lavaged 
lungs inflated with formalin as previously described [58].  
RNA purification and analysis: Total RNA was collected from BAL cell pellets with 
the miRNeasy Micro Kit and protocol (Qiagen. Valencia, CA). Primers were obtained 
from Qiagen for ATP binding cassette (ABC) transporter-A1 (Abca1, PPM03952F), 
Abcg1 (PPM03895A), chemokine (C-C motif) ligand-2 (Ccl2, PPM03151G), 
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Glyceraldehyde-3-phosphate-dehydrogenase (Gapdh, PPM02946E), peroxisome 
proliferator activated receptor-gamma (PPAR, PPM05108B) and osteopontin (Spp1, 
PPM03648C). Relative gene expression of complimentary DNA synthesized with the 
RT2 First Strand Kit was evaluated on an ABI Prism 7300 system (Applied Biosystems. 
Foster City, CA) in comparison to Gapdh using the 2-ΔΔCT method [82].  
Immunohistochemistry: BAL cytospins of freshly isolated BAL cells were fixed 
with 4% paraformaldehyde, permeabilized with 0.3% Triton-X-100 and stained for NF-
κB 1:200 (catalog# 6956S. Cell Signaling. Danvers, MA) overnight at 4⁰C followed by 
Alexa-conjugated goat anti mouse IgG 1:1000 (Invitrogen. Carlsbad, CA). Slides were 
counterstained with propidium iodide (Vector Laboratories. Burlingame, CA) to facilitate 
nuclear localization. Images were acquired on a LSM 700 confocal microscope (Zeiss. 
Oberkochen, Germany). Quantification of NF-κB nuclear localization was quantified 
using ZEN Blue software (Zeiss). Differential analysis of BAL cells revealed that alveolar 
macrophages constituted the majority of cells (93.4%-99.7%; n≥ 6) at either 10 or 20 
days post treatment with no significant differences among BAL samples from control or 
treated groups.   
Analysis of Bronchoalveolar Lavage Fluid: Total cholesterol was measured using 
the Amplex Red Cholesterol Assay kit (Thermo Fisher Scientific. Waltham, MA) 
according to manufacturer’s instructions in the presence of cholesterol esterase. 
Cholesterol was normalized to protein content of BAL Fluid measured by BCA assay 
(Thermo Fisher Scientific).  
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Quantitative Analysis of Tissue: Digital images of whole lung cross sections 
stained with hematoxylin & eosin were acquired on an Aperio ScanScope (Aperio 
Technologies, Inc. Vista, CA). Analysis was performed blindly on randomized digital 
images, scanning the entire lung at 20X magnification for pulmonary granulomas. A 
granuloma was defined as a carbon aggregate completely surrounded by tissue and 
associated with three or more cell nuclei. Quantification of total stained lung area and 
carbon content were performed by the Translational Pathology Lab (University of North 
Carolina, Chapel Hill) using the  Aperio deconvolution method as previously described 
[127]. The length (L) and width (W) of the tracheobronchal lymph node, identified based 
on Van den Broeck et al. [133], was used to determine lymph node volume using the 
formula (LxW2)π/6. 
Statistical Analysis:  All data represent the mean of at least three individual 
experiments ±SEM unless otherwise indicated. Statistical analysis was performed using 
GraphPad Prizm software (San Diego, CA). Two-tailed student’s t-tests were utilized for 





PPAR Agonist Regulates Alveolar Macrophage Gene Expression 10 days post 
MWCNT-Instillation 
Our previous studies have shown deficiency of PPAR, ABCA1 and ABCG1 in 
alveolar macrophages from both sarcoidosis patients and the 60 day MWCNT model 
[16;35;59]. The inflammatory mediators, chemokine (C-C motif) ligand-2 (CCL2) and 
osteopontin, were elevated in sarcoidosis granulomatous tissue and in the 60 day 
MWCNT model [15;59;103;108]. In the present study we evaluated gene expression of 
alveolar macrophages isolated 10 days following MWCNT instillation. PPAR, ABCA1 
and ABCG1 expression were significantly decreased in MWCNT instilled animals 
compared to those receiving vehicle (Figure 1A). As expected, the expression of CCL2 
and osteopontin was upregulated in MWCNT instilled mice (Figure 1B). To determine 
the optimal dose of rosiglitazone required to increase alveolar macrophage ABCG1 
expression and decrease the expression of pro-inflammatory mediators, rosiglitazone 
was administered at 2, 6 or 12mg/kg/day. The expression of alveolar macrophage 
ABCG1 was significantly increased in animals receiving 6 and 12mg/kg diet (Figure 1C). 
Evaluation of pro-inflammatory mediators found rosiglitazone capable of limiting CCL2 
and osteopontin expression in a dose-dependent manner (Figure 1D,E). The optimal 
dose of rosiglitazone required to increase alveolar macrophage ABCG1 and limit pro-
inflammatory mediator expression was 6mg/kg (Figure 1). 
Histological examination of lung morphology confirmed our previous observation 
that granulomas at 10 days post-instillation were loosely formed [58]. Evaluation of the 
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frequency and severity of granulomatous inflammation using a previously described 
scoring system [59], found no difference between MWCNT instilled animals given 
rosiglitazone and normal chow (data not shown). To determine if the continuation of 
rosiglitazone would limit pulmonary granuloma formation, animals were evaluated 20 
days post MWCNT instillation. 
Rosiglitazone Inhibits MWCNT induced Pulmonary Granuloma Formation 
Quantitative measurements were performed on digital images of lung tissue from 
MWCNT instilled mice receiving normal chow or the optimal dose of rosiglitazone 
(6mg/kg). The administration of rosiglitazone 20 days post-instillation: 1) significantly 
decreased the number of granulomas per lung area (Figure 2A); 2) limited the size of 
granulomatous lesions (Figure 2B); and 3) reduced the total carbon deposition in the 
lungs compared to animals receiving normal chow (Figure 2C).  During gross dissection 
of the thoracic cavity, carbon deposition was noted in the cranial mediastinal lymph 
node. Quantification of lymph node volume revealed a significant increase following 
MWCNT instillation compared to mice receiving vehicle, and further lymphadenopathy 
in animals receiving rosiglitazone (Figure 2D). As a measure of total lung injury, protein 
concentration of the BAL fluid (BALF) was evaluated. MWCNT instillation resulted in 
significantly higher BALF protein concentration compared to animals receiving vehicle, 
while administration of rosiglitazone attenuated this increase (Figure 2E). 
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Rosiglitazone limits Alveolar Macrophage Activation and Pulmonary Dyslipidemia 
following MWCNT Instillation 
Administration of rosiglitazone (6mg/kg) significantly attenuated the expression of 
alveolar macrophage CCL2 and osteopontin expression 20 days post MWCNT 
instillation (Figure 3B/C). We performed further studies to determine the mechanism by 
which rosiglitazone limited pro-inflammatory gene expression. PPAR is capable of 
limiting pro-inflammatory gene expression through trans-repression of NF-κB activity 
[47;115]. Analysis of alveolar macrophages from MWCNT instilled mice demonstrated 
significantly less nuclear p65 localization in animals receiving rosiglitazone laden diet 
compared to controls (Figure 3A). 
Decreased expression of alveolar macrophage PPAR, ABCA1 and ABCG1 was 
also observed 20 days post MWCNT instillation (Figure 4A-C).  Rosiglitazone did not 
affect the expression of PPAR or ABCA1 (Figure 4A, B). In comparison, expression of 
alveolar macrophage ABCG1, a target gene of PPAR, was significantly increased in 
MWCNT instilled mice receiving rosiglitazone compared to those receiving normal chow 
(Figure 4C). CD36 expression is slightly increased in MWCNT instilled animals, but was 
further up-regulated in animals receiving rosiglitazone (Figure 4D). To assess the rate of 
alveolar macrophage lipid catabolism we evaluated intracellular and extracellular lipids.  
Intracellular lipid accumulation was evaluated by determining mean alveolar 
macrophage diameter. Mice instilled with MWCNT had significantly larger alveolar 
macrophages compared to controls, while administration of rosiglitazone attenuated the 
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increase in cell size (Figure 4E). Total cholesterol accumulation in BAL fluid following 




We have described a murine model of MWCNT induced granulomatous lung 
disease which closely mimics pulmonary sarcoidosis, including the deficiency of 
alveolar macrophage PPAR. The ablation of alveolar macrophage PPAR exacerbates 
MWCNT induced pulmonary granulomatous disease as well as pro-inflammatory 
alveolar macrophage activation [59]. Here we demonstrate that the PPAR agonist 
rosiglitazone significantly limits alveolar macrophage activation, pulmonary granuloma 
formation and pulmonary lipid dysregulation following MWCNT instillation. These 
observations suggest that regulation of alveolar macrophage PPAR may serve as a 
novel target for limiting pulmonary granulomatous inflammation.  
Pretreatment with rosiglitazone limited the expression of pro-inflammatory 
mediators following MWCNT instillation. PPAR can regulate inflammatory gene 
expression by trans-repression, the ability to interfere with the activity of other 
transcription factors such as NF-κB [47;115].  Alveolar macrophages of pulmonary 
sarcoidosis patients have significantly higher NF-κB activation compared to healthy 
individuals [35]. Our studies demonstrate that rosiglitazone inhibits NF-κB nuclear 
localization in MWCNT instilled animals. This observation is consistent with an inverse 
relationship between PPAR and NF-κB activity. Additionally, CCL2 and osteopontin 
expression are regulated by NF-κB activity [89;148]. Interestingly, CCL2 or osteopontin-
deficient mice develop less severe pulmonary granulomas in response to infectious 
stimuli [83;104]. These data suggest that such mediators may play a role in granuloma 
progression. The upregulation of these mediators in both human sarcoidosis and in 
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MWCNT instilled mice, beginning as early as ten days post instillation, also supports a 
critical role for these mediators in pulmonary granulomatous disease progression. 
The frequency and severity of granulomatous lesions are attenuated by 
rosiglitazone 20 days post MWCNT instillation. The reduction of BAL fluid protein 
concentration in rosiglitazone treated animals also suggests attenuation of total lung 
injury. Previous reports have noted BAL fluid albumin concentration increased in a dose 
dependent manner following MWCNT instillation [112]. In addition to the decrease in 
frequency and severity of granulomas 20 days post-instillation, a decrease in pulmonary 
carbon content was also observed. Inhaled particulate matter has been shown to clear 
through pulmonary lymphatics [2;126]. The increase in mediastinal lymph node volume 
may suggest that carbon is cleared through this pathway when not incorporated into 
granuloma. Changes in mediastinal lymphadenopathy warrant further study with regard 
to carbon content and identity of lymph node cells. 
In this report, we show the treatment with rosiglitazone significantly limits 
MWCNT induced pulmonary lipid accumulation. Our previous studies have shown 
alveolar macrophages of 60 day MWCNT instilled animals have increased intracellular 
lipid accumulation, a phenotype which promotes pro-inflammatory signaling in ABC-lipid 
transporter deficient macrophages [16;147]. Our data suggest that rosiglitazone 
increases alveolar macrophage lipid catabolism by promoting uptake and export, by the 
PPAR target genes CD36 and ABCG1. The slight increase of CD36 expression 
observed in alveolar macrophages of MWCNT instilled animals may be attributed to 
increased intracellular lipid content. Oxidized lipids have been shown to promote CD36 
expression in a PPAR-independent mechanism [36]. These observations suggest that 
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pulmonary lipid dysregulation following exposure to MWCNT may contribute to alveolar 
macrophage pro-inflammatory activation. 
The current findings support and confirm our previous study examining the role of 
PPAR deficiency in granulomatous disease [59]. Whereas PPAR deficiency 
exacerbates granulomatous disease, ligand-dependent induction of PPAR activity 
exerts a protective effect and constrains granuloma size. These data also strongly 
suggest that the PPAR pathway responsible for the protective effect is the regulation 















Figure 1: Rosiglitazone Regulates Alveolar Macrophage Gene Expression 10 days 
following MWCNT instillation.  Quantitative-PCR analysis of the lipid regulatory genes 
(A) peroxisome proliferator activated receptor- (PPAR), ATP-binding cassette lipid 
transporter-G1 (ABCG1), and ABCA1; and inflammatory mediators (B) CCL2 and 
osteopontin (OPN) in BAL cells of vehicle or MWCNT instilled mice.  Effect of 
rosiglitazone dose curve on alveolar macrophage (C) ABCG1, (D) CCL2 and (E) 











































































































































































































Figure 2: Rosiglitazone Inhibits Pulmonary Granuloma Formation 20 days post 
MWCNT Instillation.  Quantitative analysis of H&E stained lung tissue was utilized to 
evaluate (A) the average number of granulomas, (B) average granuloma size, (C) and 
total carbon deposition in MWCNT instilled animals receiving normal chow or 
rosiglitazone (6mg/kg).  Evaluation of (D) mediastinal lymph node volume and (E) BAL-
fluid protein concentration in vehicle and MWCNT instilled animals receiving normal 











































































































































































Figure 3: Rosiglitazone Reduces Alveolar Macrophage Activation 20 days post 
MWCNT Instillation.  (A) Mean fluorescence intensity of nuclear NF-κB p65 protein in 
MWCNT instilled animals receiving normal chow or rosiglitazone (6mg/kg), 
≤99cells/animal. Quantitative-PCR analysis of (B) CCL2 and (C) osteopontin expression 
in BAL cells of vehicle or MWCNT instilled animals receiving normal chow or 









































































































































Figure 4: Rosiglitazone limits pulmonary dyslipidemia 20 days following MWCNT 
instillation.  Quantitative-PCR analysis of the lipid regulatory genes (A) PPAR (B) 
ABCA1, (C) ABCG1 and (D) CD36 in vehicle or MWCNT instilled animals receiving 
normal chow or rosiglitazone (6mg/kg).  Evaluation of (E) mean alveolar macrophage 
diameter and (E) total cholesterol content of BAL fluid of vehicle and MWCNT instilled 
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 Our laboratory has described a murine model of chronic granulomatous 
inflammation elicited by multiwall carbon nanotubes which bears striking similarity to 
pulmonary sarcoidosis. Alveolar macrophages of sarcoidosis patients and MWCNT 
instilled mice demonstrate 1) decreased expression and activity of PPAR, 2) decreased 
expression of the lipid transporters ABCA1 and ABCG1 and 3) increased expression of 
the pro-inflammatory mediators CCL2 and osteopontin. Further investigation found that 
macrophage-specific deficiency of PPAR promotes MWCNT induced granuloma 
formation, inflammation and fibrosis [59;86]. These studies aimed to further determine 
how these factors contributed to pulmonary granuloma formation and inflammation. We 
hypothesized that the deficiency of the PPAR-ABCG1 pathway and subsequent 
pulmonary lipidosis promote MWCNT induced granuloma formation. 
Here we demonstrate that the deficiency of ATP binding cassette lipid transporter 
ABCG1, but not ABCA1, promotes pulmonary granuloma formation, pulmonary fibrosis, 
pro-fibrotic mediators and the expression of CCL2 and osteopontin. We further 
demonstrate the administration of the PPAR specific agonist rosiglitazone increased 
the expression of alveolar macrophage ABCG1, reduced pulmonary lipid accumulation 
and limits the formation of pulmonary granulomas and the expression of the pro-
inflammatory mediators CCL2 and osteopontin. The data presented here demonstrate 
the deficiency of alveolar macrophage ABCG1 is not only an effect of, but actively 
promotes pulmonary inflammation and injury. These studies also support our hypothesis 




Several questions arise from the work reported in this dissertation. An 
unexpected difference found during this study was PPAR mRNA expression. 
Significantly downregulated in wild-type alveolar macrophages, PPAR mRNA 
expression in ABC-lipid transporter knockout animals demonstrate a slight but 
nonsignificant decrease compared to wild-type mice and was not affected by MWCNT 
instillation. Further studies will be required to evaluate the activity of PPAR nuclear 
activity in these cells. Preliminary observations suggest the ABCG1-KO and 
ABCA1/ABCG1-DKO models exhibit increased lipid accumulation and general 
pulmonary inflammation compared to PPAR-KO mice. Paradoxically, the MWCNT 
induced granulomas in PPAR-KO mice are more concentric and well organized 
compared to the irregular borders and multiple carbon aggregates observed in ABCG1-
KO and ABCA1/ABCG1-KO mice. This observations may suggest the lung environment 
is more dynamic in ABCG1 deficient animals. Previous studies have indicated ABCG1 
deficiency promotes leukocyte infiltration into the airways and lung interstitium [40;143]. 
Visual observation of ABCG1-KO animals following MWCNT instillation also noted 
increased bronchial associated lymphoid tissue and lymphoid aggregates throughout 
the lung compared to wild-type animals. Characterization of the infiltrating leukocytes in 
the airways and pulmonary interstitium may lead to a better understanding of how the 
pulmonary granuloma is formed and maintained. 
Another area of interest is the identification of specific mechanisms regulating 
pulmonary lipid accumulation and inflammation. Macrophage lipid accumulation has 
been shown to increase the sensitivity of these cells to pro-inflammatory ligands. 
Increased cholesterol content of the plasma membrane promotes the formation of lipid-
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rafts, which organize cell signaling molecules such as toll-like receptors [74;147]. Toll 
like receptors recognize pathogens and endogenous damage associated molecular 
patterns which enhance the inflammatory response [69]. The role of these receptors 
have also been investigated in the pathology of sarcoidosis. Genetic association studies 
have identified the TLR4 and TLR9 genes with development of sarcoidosis [122;123]. 
Further studies demonstrated bronchoalveolar lavage (BAL) cells of sarcoidosis 
patients’ exhibit increase cytokine production in response to TLR2 ligands and have 
significantly higher TLR9 mRNA expression and alveolar macrophage protein content 
compared to controls individuals [44;121]. Interestingly, TLR4 ligands have been shown 
to inhibit PPAR mRNA expression in an NF-κB dependent mechanism [100]. 
In addition to promoting toll-like receptor signaling, dysregulation of cholesterol 
homeostasis has been found to activate the NLRP3 inflammasome [42]. The 
inflammasome is a multimeric protein complex which proteolytically activates 
interleukin-1β (IL-1β) [38]. Evaluation of alveolar macrophages from a large cohort of 
sarcoidosis patients found a significant increase in NLRP3 mRNA expression and 
reduced granuloma formation in a NLRP3 deficient murine model [113]. The 
inflammasome has also been implicated in promoting MWCNT induced acute 
inflammation and induction of pro-fibrotic mediators [48;60]. During the course of our 
studies, we observed the administration of rosiglitazone limits MWCNT induced IL-1β 
expression 20 days following MWCNT instillation. 
 Changes in lipid homeostasis have also been implicated in the regulation of the 
adaptive immune response [42;138]. Deficiency of ABCG1 has been found to promote 
lymphocyte infiltration and the production of autoantibodies against oxidized lipid 
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species of the lung [9;143]. In sarcoidosis, activated T-cells propagate the inflammatory 
process [51]. Elevated CD4/CD8 ratio is commonly associated with pulmonary 
sarcoidosis and has been established as a strong diagnostic indicator of the disease 
[137;142]. Our studies found the deficiency of macrophage ABCG1 promotes MWCNT 
induced mediastinal lymphadenopathy, suggesting an effect on adaptive immune 
programs. Increasing our understanding of these interactions may lead to improved 
therapies. 
 Currently there are limited treatment options available for pulmonary sarcoidosis, 
those include corticosteroids, immunosuppressive agents and biologics. Corticosteroids 
have been shown to be modestly effective and are commonly the initial treatment option 
in patients who do not undergo spontaneous remission [21;62;111]. However there are 
significant side effects associated with these agents, particularly when used for 
extended periods of time [21]. Immunosuppressive agents have also been utilized 
during steroid-sparing periods and for individuals who do not tolerate steroids well [22]. 
More recently the use of biologics have been evaluated. The use of TNFα (tumor 
necrosis factor-α) inhibitors such as Infliximab or Thalidomide, which limits TNFα 
release from alveolar macrophages have been shown to be effective in refractory 
sarcoidosis [21]. Given these observations other clinical options may improve the 
clinical outcomes of sarcoidosis.  
 Recent studies have indicated cholesterol regulatory genes may serve as novel 
pharmacological targets in the treatment of lung disease. The subject of a recent 
comprehensive review [50], cholesterol targeting agents have been utilized in 
experimental models of asthma, acute lung injury, COPD and pulmonary fibrosis. A 
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recent clinical trial (NCT00279708) has evaluated the use of the cholesterol targeting 
agent atorvastatin to extend the amount of time pulmonary sarcoidosis patients were 
taken off or given reduced doses of corticosteroids. Individuals randomized into the 
control group averaged 257 days until steroids were resumed while those individuals 
receiving Atorvastatin averaged 301 days, however no statistical data or follow up 
outcome measures have been provided. In addition to regulating hepatic lipid synthesis, 
statins are known to have anti-inflammatory properties through inhibition of NFκB but 
also promote the activity of PPAR [66]. These observation prompt the question, could a 
similar retrospective study be conducted evaluating patients receiving a direct PPAR 
agonist such as rosiglitazone or another thiazolidinedione? 
 The work presented here addresses the role of PPAR, ABCG1 and lipid 
accumulation in granulomatous lung disease. We hypothesized that the PPAR-ABCG1 
pathway and pulmonary lipid accumulation would exacerbate granulomatous 
inflammation. These data indicate there is a unique relationship between pulmonary 
lipid homeostasis and inflammatory lung disease and understanding this relationship will 
contribute to the development of novel therapies for inhibiting inflammation in response 
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